A Phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease

Manuscript Number: 

16-0369R1

Author(s): 
Kevin Booth, H. Robert Brashear, Mark Brody, Jianing Di, Enchi Liu, Ming Lu, Richard A. Margolin, Gerald Novak, Anna Shadman, John L. Werth

Disclosures

Kevin Booth

  • Equity:
    Equities (Pfizer, Inc. stock): Pfizer employee stock plan: 1,583.8 shares as of 06/30/16 401K account: 3,075.5 shares as of 06/30/16 Pfizer stock options (employee plan): 30,458 shares (21,837 exercisable) as of 06/30/16
    Sponsors:
    Pfizer, Inc (legacy Wyeth). 2005- present

H. Robert Brashear

  • Equity:
    I am an employee of Janssen Research and Development, LLC, and own stock and stock options in the company.
    Sponsors:
    I am an employee of Janssen Research and Development, LLC, and own stock and stock options in the company.

Mark Brody

  • Nothing to Disclose

Jianing Di

  • Equity:
    long term incentive for Janssen full time employees.

Enchi Liu

  • Sponsors:
    During the trial conduct and drafting of the manuscript, i was an employee of Janssen R&D during which i received a salary and company stocks. Currently I am employed by Prothena Biosciences and no longer own any Janssen stock.

Ming Lu

  • Equity:
    Owner of JNJ stock
    Sponsors:
    Full time employee of Janssen R&D, a subsidiary of Johnson & Johnson

Richard A. Margolin

  • Equity:
    Merck stock; Johnson and Johnson stock

Gerald Novak

  • Equity:
    Stock owned in Johnson & Johnson - I am an employee of the same
    Sponsors:
    I am a senior Director and I had experience as the clinical leader of the bapineuzumab subcutaneous program, and was the study responsible physician for the clinical trial reported in this ppaer

Anna Shadman

  • Equity:
    J&J stocks. Approx $700k
    Sponsors:
    No longer employed but was an employee of J&J at the time of study.

John L. Werth

  • Equity:
    I own shares of Pfizer common stock and have options to purchase additional shares.
    Sponsors:
    Full time employee of Pfizer, Inc.